文献速递药物相互作用

口服司美格鲁肽对左炔诺孕酮/炔雌醇、呋塞米和瑞舒伐他汀药代动力学的影响

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
PubMed 文献 · Clin Pharmacokinet · 2021-01-01

两项单序列交叉试验在健康绝经后女性(n=25)和健康受试者(n=41)中评估口服司美格鲁肽及SNAC对炔雌醇、左炔诺孕酮、呋塞米和瑞舒伐他汀药代动力学的影响。结果显示口服司美格鲁肽不影响炔雌醇和左炔诺孕酮的AUC和Cmax;呋塞米和瑞舒伐他汀AUC分别增加至1.28和1.41倍,但被认为无临床相关性。

要点

  • 口服司美格鲁肽不影响炔雌醇和左炔诺孕酮的暴露量。
  • 呋塞米和瑞舒伐他汀AUC分别增至1.28倍和1.41倍,无临床相关性。
  • SNAC单用不影响炔雌醇、左炔诺孕酮或瑞舒伐他汀的AUC或Cmax。

核心结论

  • 口服司美格鲁肽与炔雌醇或左炔诺孕酮合用时未影响其药代动力学。
  • 口服司美格鲁肽使呋塞米和瑞舒伐他汀暴露量小幅增加,但不预期有临床相关性。

研究设计与样本

  • 两项单独的单序列交叉试验:试验1纳入健康绝经后女性(n=25),试验2纳入健康男性和女性受试者(n=41)。
  • 受试者分别单独给药、与SNAC单用或与口服司美格鲁肽合用。
  • 药物相互作用判定标准为AUC或Cmax比值的90%CI在0.80-1.25内。

主要发现

  • 炔雌醇和左炔诺孕酮AUC的估计比值(90%CI)分别为1.06(1.01-1.10)和1.06(0.97-1.17),Cmax未受影响。
  • 呋塞米和瑞舒伐他汀AUC的估计比值(90%CI)分别为1.28(1.16-1.42)和1.41(1.24-1.60),未满足无效应标准;Cmax同样未满足。
  • SNAC单用不影响炔雌醇、左炔诺孕酮或瑞舒伐他汀的AUC或Cmax;呋塞米Cmax略有降低。
  • 不良事件与既往GLP-1RA观察结果相似。

关键数值与推荐

  • 无药物相互作用判定标准:AUC或Cmax比值的90%CI落在0.80-1.25内。

临床怎么用

  • 口服司美格鲁肽与口服避孕药(炔雌醇/左炔诺孕酮)合用时无需调整避孕药剂量。
  • 与呋塞米或瑞舒伐他汀合用时,暴露量小幅增加但无临床相关性,无需常规剂量调整。

局限性

  • 试验为单序列交叉设计,非随机双盲对照。
  • 样本量较小(试验1 n=25,试验2 n=41)。
  • 受试者为健康人群,未纳入患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) comprises semaglutide co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). Oral semaglutide may alter the pharmacokinetics of co-administered drugs via effects of semaglutide or SNAC. Two separate one-sequence crossover trials investigated the effects of oral semaglutide and SNAC on the pharmacokinetics of ethinylestradiol, levonorgestrel, furosemide and rosuvastatin. METHODS: Healthy, postmenopausal women (n = 25) received once-daily combined ethinylestradiol and levonorgestrel (Trial 1) and healthy male and female subjects (n = 41) received single doses of furosemide and rosuvastatin (Trial 2), either alone, with SNAC alone or with oral semaglutide. Lack of drug-drug interaction was concluded if 90% confidence intervals (CIs) for the ratio of area under the plasma concentration-time curve (AUC) or maximum concentration (Cmax), with/without oral semaglutide, were within a pre-specified interval (0.80-1.25). RESULTS: The AUC values of ethinylestradiol and levonorgestrel were not affected by oral semaglutide co-administration (estimated ratios [90% CI] 1.06 [1.01-1.10] and 1.06 [0.97-1.17], respectively); Cmax was not affected. The no-effect criterion was not met for furosemide or rosuvastatin for the AUC (1.28 [1.16-1.42] and 1.41 [1.24-1.60], respectively) or Cmax. SNAC alone did not affect the AUC or Cmax of ethinylestradiol, levonorgestrel or rosuvastatin; the Cmax of furosemide was slightly decreased. Adverse events were similar to those previously observed for GLP-1RAs (both trials). CONCLUSION: Co-administration with oral semaglutide did not affect the pharmacokinetics of ethinylestradiol or levonorgestrel. There was a small increase in exposure of furosemide and rosuvastatin; however, these increases are not expected to be of clinical relevance. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02845219 and NCT03010475.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Jordy AB, Albayaty M, Breitschaft A, et al. Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. Clin Pharmacokinet. 2021. PMID: 33782832. doi:10.1007/s40262-020-00976-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。